Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 3 Neoplasm Metastasis 2 Small Cell Lung Carcinoma 1 Sarcoma 1 Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Advanced Primary Liver Cancer 1

Interventions

Carboplatin 42 Etoposide 37 Cisplatin 23 Topotecan 22 Nivolumab 17 pembrolizumab 12 atezolizumab 12 Ipilimumab 10 Paclitaxel 9 durvalumab 8 Irinotecan 8 Radiosurgery 6 Pemetrexed 6 rovalpituzumab tesirine 5 Magnetic Resonance Spectroscopy 5 trioctyl phosphine oxide 4 trilaciclib 4 etoposide phosphate 4 berzosertib 4 Sunitinib 4 Specimen Handling 4 Platinum 4 PM 01183 4 Dexamethasone 4 veliparib 3 tremelimumab 3 olaparib 3 carfilzomib 3 cabozantinib 3 Temozolomide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Small Cell Lung Carcinoma × apatinib × Clear all

NCT03417895 2024-08-07

PASSION

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed

59 enrolled 17 charts

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡